Propulsion of Malignant Mesothelioma Pipeline as Novel and Extensive Therapies Enter the Treatment Domain, Anticipates DelveInsight
Malignant Mesothelioma is a rare growth of mesothelial cells strongly associated with asbestos exposure. Major pipeline molecules include durvalumab, pembrolizumab, tremelimumab, nintedanib, ADI-PEG 20, and MesoPher. Additionally, the development of novel therapies is going to introduce advanced treatment options.
Las Vegas, USA, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Propulsion of Malignant Mesothelioma Pipeline as Novel and Extensive Therapies Enter the Treatment Domain, Anticipates DelveInsight
Malignant Mesothelioma is a rare growth of mesothelial cells strongly associated with asbestos exposure. Major pipeline molecules include durvalumab, pembrolizumab, tremelimumab, nintedanib, ADI-PEG 20, and MesoPher. Additionally, the development of novel therapies is going to introduce advanced treatment options.
DelveInsight’s ‘Malignant Mesothelioma Pipeline Insight 2021’ report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, key companies working to advance the pipeline space, and future growth potential of the Malignant Mesothelioma pipeline domain.
Some of the crucial points taken from the Malignant Mesothelioma Pipeline report:
- DelveInsight’s Malignant Mesothelioma Pipeline analysis depicts the space with 25+ active players working to develop 25+ pipeline therapies.
- Major pharmaceutical companies that are developing potential drug candidates to improve the Malignant Mesothelioma treatment scenario include Momotaro-Gene, Polaris Group, Amphera, Vivace Therapeutics, MedImmune, TCR2 Therapeutics, Atara Biotherapeutics, Inhibrx, Eisai, Targovax, Merck & Co, Bayer HealthCare, SELLAS Life Sciences Group, CanBas, FKD Therapies, Virttu Biologics, MolMed, Ys Therapeutics, LIPAC Oncology, TCR2 Therapeutics, Hutchison Medipharma Limited, Clovis Oncology, Sanofi, Merck & Co., PharmaMar, Targovax and many others.
- Key Malignant Mesothelioma pipeline therapies such as rAd-IFN, Pembrolizumab, ADI-PEG 20, MesoPher, MTG201, HMPL-453, SAR444245, Rucaparib, TC 210, iCasp9M28z T-cell, INBRX-109, VT3989, LEITP-1009, YS110, Gavo-cel, iCasp9M28z T-cell, Lurbinectedin, ONCOS-102 and others are under investigation in different phases of clinical trials.
- Targovax initiated a randomized, phase I/II clinical trial combining ONCOS-102 with Pem-Cis in 31 patients, indicating that ONCOS-102 can activate the immune system and increase tumour infiltrating T-cells into Malignant Pleural Mesothelioma.
- Sellas Life Sciences Group is evaluating Galinpepimut-S (GPS) for the treatment of Malignant Mesothelioma. It is an immunotherapy that targets the Wilms Tumor 1 (WT1) protein which is present and over-expressed in an array of hematologic malignancies and solid tumors.
- LIPAC is developing a new Liposomal Enhanced IntraThoracic Paclitaxel (LEITP) for the treatment of Malignant Pleural Mesothelioma utilizing the LiPax technology. Preclinical studies with LEITP-1009 are underway.
- In July 2021, PharmaMar announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has given its positive opinion for Orphan Drug Designation to Zepzelca (lurbinectedin) for the treatment of Malignant Mesothelioma.
- UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase.
- Momotaro-Gene is evaluating MTG201, a novel investigational gene therapy with unique dual mechanisms of action capable of addressing a range of cancers. A Phase II clinical trial is being conducted at the Baylor College of Medicine in Houston, Texas.
Track which potential therapy is anticipated to take charge of Malignant Mesothelioma pipeline in the forthcoming years by requesting a sample @ Malignant Mesothelioma Emerging Therapies and Forecast
The Malignant Mesothelioma pipeline report lays down detailed profiles of the pipeline assets, inactive and dormant assets, comparative analysis of clinical and non-clinical stage Malignant Mesothelioma products, comprehensive assessment of driving and restraining factors, along with the opportunities and risks in the Malignant Mesothelioma pipeline landscape.
Malignant Mesothelioma Overview
Malignant Mesothelioma is a rare, incurable, asbestos-related cancer. It mainly affects the lining of the lung and chest cavity (pleura) or lining of the abdomen (peritoneum). In rare cases, mesothelioma tumors can grow in the linings of the heart (pericardium) or testes (tunica vaginalis).
There are 4 types of mesothelioma, each affecting a different area in the body. The four types are pleural mesothelioma, peritoneal mesothelioma, pericardial mesothelioma, and testicular mesothelioma.
Explore more about Malignant Mesothelioma pipeline therapeutics assessment @ Malignant Mesothelioma Pipeline Assessment
Malignant Mesothelioma Pipeline Drugs
| Drug | Company | Phase | MoA | RoA |
| rAd-IFN | Trizell Ltd | III | IFNA2B expression stimulants | NA |
| Pembrolizumab | Merck & Co | III | Programmed cell death-1 receptor antagonists | Intravenous |
| ADI-PEG 20 | Polaris Pharmaceuticals | II/III | Arginine deiminase replacements | Intramuscular |
| MesoPher | Amphera | II/III | Immunostimulant | Intradermal |
| MTG201 | Momotaro-Gene | II | DKK3 expression modulators | Intratumoural |
| HMPL-453 | Hutchison Medipharma Limited | II | Type 1, 2, 3 1 fibroblast growth factor receptor antagonists | Oral |
| SAR444245 | Sanofi | II | Interleukin-2 replacements | Intravenous |
| Rucaparib | Clovis Oncology | II | Poly(ADP-ribose) polymerase 1, 2, 3 inhibitors | Oral |
| TC 210 | TCR2 Therapeutics | I/II | Immunologic cytotoxicity; T lymphocyte replacements | NA |
| iCasp9M28z T-cell | Bellicum Pharmaceuticals | I/II | Immunologic cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte replacements | NA |
| INBRX-109 | Inhibrx | I | TRAIL receptor 2 agonists | Parenteral |
| VT3989 | Vivace Therapeutics | I | Transcription factor inhibitors | Oral |
| LEITP-1009 | LIPAC Oncology | Preclinical | Proto-oncogene protein c-bcl-2 inhibitors | NA |
Request for Sample to know more @ Malignant Mesothelioma Pipeline Analysis and Key Companies
Malignant Mesothelioma Therapeutics Assessment
The Malignant Mesothelioma Pipeline report proffers an integral view of the Malignant Mesothelioma emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, and Mechanism of Action.
By Product Type
- Mono
- Combination
- Mono/Combination
By Stage
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
By Route of Administration
- Subcutaneous
- Intravenous
- Oral
- Inhalation
By Molecule Type
- Gene therapy
- Stem cell therapy
- Small molecules
By Mechanism of Action
- Protease inhibitors
- Immunomodulatory
- Immunologic cytotoxicity; Programmed cell death-1 receptor antagonists;
- Proto-oncogene protein c-bcl-2 inhibitors
- TRAIL receptor 2 agonists
- Transcription factor inhibitors
- Type 1, 2, 3 1 fibroblast growth factor receptor antagonists
- Interleukin-2 replacements
- IFNA2B expression stimulants
- Arginine deiminase replacements
Scope of the Malignant Mesothelioma Pipeline Report
- Coverage: Global
- Major Players: Momotaro-Gene, Polaris Group, Amphera, Vivace Therapeutics, MedImmune, TCR2 Therapeutics, Atara Biotherapeutics, Inhibrx, Eisai, Targovax, Merck & Co, Bayer HealthCare, SELLAS Life Sciences Group, CanBas, FKD Therapies, Virttu Biologics, MolMed, Ys Therapeutics, LIPAC Oncology, TCR2 Therapeutics, Hutchison Medipharma Limited, Clovis Oncology, Sanofi, Merck & Co., and others.
- Key Malignant Mesothelioma Pipeline Therapies: rAd-IFN, Pembrolizumab, ADI-PEG 20, MesoPher, MTG201, HMPL-453, SAR444245, Rucaparib, TC 210, iCasp9M28z T-cell, INBRX-109, VT3989, LEITP-1009, YS110, Gavo-cel, iCasp9M28z T-cell, and several others.
Gain rich insights into emerging therapies @ Malignant Mesothelioma Pipeline Emerging Novel Therapies
Table of Contents
| 1 | Introduction |
| 2 | Executive Summary |
| 3 | Malignant Mesothelioma: Overview |
| 4 | Pipeline Therapeutics |
| 5 | Malignant Mesothelioma: Late Stage Products (Pre-registration) |
| 6 | Malignant Mesothelioma: Late Stage Products (Phase III) |
| 6.1 | rAd-IFN: Trizell Ltd |
| 7 | Malignant Mesothelioma: Mid Stage Products (Phase II) |
| 7.1 | HMPL-453: Hutchison Medipharma Limited |
| 8 | Malignant Mesothelioma: Early Stage Products (Phase I) |
| 8.1 | INBRX-109: Inhibrx |
| 9 | Pre-clinical and Discovery Stage Products |
| 9.1 | LEITP-1009: LIPAC Oncology |
| 10 | Therapeutic Assessment |
| 11 | Inactive Products |
| 12 | Malignant Mesothelioma - Unmet Needs |
| 13 | Malignant Mesothelioma - Market Drivers and Barriers |
| 14 | Appendix |
| 15 | About DelveInsight |
Discover more about the scope of the report @ Malignant Mesothelioma Treatments Therapies and Ongoing Clinical Trials
Track and assess candidate’s clinical development journey here @ Profiling and Comparative Therapeutic Assessment
Related Reports
DelveInsight's "Malignant Mesothelioma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Malignant Mesothelioma, historical and forecasted epidemiology, market share of the individual therapies, treatment practice/algorithm, market drivers, market barriers, and unmet needs.
Malignant Mesothelioma Epidemiology
DelveInsight's 'Malignant Mesothelioma - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Malignant Mesothelioma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
DelveInsight’s ‘Cervical Cancer –Market Insights, Epidemiology, and Market Forecast-2030’ report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology, current treatment practices, market share of the individual therapies, and key companies involved like Genentech/Roche, Iovance Biotherapeutics, Amgen/Allergan, AstraZeneca, Avastin Biosimilars, GlaxoSmithKline/Novartis, Merck Sharp & Dohme, Pfizer, Seattle Genetics/ Genmab, Vaccibody, Zeria Pharmaceutical, and many others.
DelveInsight's "Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of Prostate cancer, historical and forecasted epidemiology, emerging drugs, and key companies involved like Bayer Health Care, Astellas Pharma, Amgen, Janssen Pharmaceutical, Sanofi, AstraZeneca/ Merck Sharp & Dohme, Bristol-Myers Squibb, Novartis, Myovant Sciences/Takeda, Hoffmann-La Roche, Pfizer, Clovis Oncology, Regeneron Pharmaceuticals, t, Suzhou Kintor Pharmaceutical, Eli Lilly and Company, and several others.
Non-Small Cell Lung Cancer (NSCLC) Market
DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology, emerging drugs, market share, and key companies involved like Novartis Pharmaceuticals, AbbVie, Janssen Pharmaceuticals, Xcovery, Eli Lilly and Company, Sanofi, Pfizer, Takeda Pharmaceuticals, Incyte Corporation, and others.
Acute Myeloid Leukemia Pipeline
DelveInsight’s, “Acute Myeloid Leukemia (AML) - Pipeline Insight, 2021,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Acute Myeloid Leukemia (AML) pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, key companies including BioSight, GlycoMimetics, Novartis, Takeda, Menarini Group, ImmunoGen, Kartos Therapeutics, Plexxikon, Shijiazhuang Yiling Pharmaceutical, Oscotec, Ryvu Therapeutics, and several others.
Checkpoint Inhibitor Refractory Cancer Market
DelveInsight’s ‘Checkpoint Inhibitor Refractory Cancer—Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Checkpoint Inhibitor Refractory Cancer, historical and forecasted epidemiology, market drivers, market barriers, unmet medical needs, and key companies involved like Bristol-Myers Squibb, AstraZeneca, Merck, Genentech/Hoffmann-La Roche, Regeneron Pharmaceuticals, Merck KGaA, and Pfizer, Bristol-Myers Squibb, Janssen Research and Development, Eisai, Kartos Therapeutics, Immunity Bio, and many others.
DelveInsight's 'Multiple Myeloma (MM)-Market Insights, Epidemiology and Market Forecast—2030' report offers rich insights into current and emerging treatments, pipeline therapies, and key pharmaceuticals including GlaxoSmithKline, Bristol-Myers Squibb/Bluebird bio, Oncopeptides AB, Secura Bio, Sanofi, Janssen Biotech, Celgene, Pfizer (Array Biopharma), Chipscreen Biosciences, Merck, Regeneron Pharmaceuticals, AstraZeneca, MorphoSys AG/I-Mab Biopharma, and many others.
Acute Agitation And Aggression Market
DelveInsight's "Acute Agitation And Aggression- Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Acute Agitation And Aggression, historical and forecasted epidemiology, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Browse Through Our Blog Posts
Malignant Pleural Mesothelioma Upcoming Therapies
The Malignant Pleural Mesothelioma treatment market includes several immunotherapy agents, in the pipeline including Keytruda, Opdivo and Yervoy, which have shown promising anticancer activity against mesothelioma in recent clinical trials.
Malignant pleural mesothelioma market: Elusive treatment approaches and Poor diagnosis
Malignant pleural mesothelioma (MPM) is a malignancy of pleural layers within the lung cavity and inner sides of the ribs. A Year of research has revealed asbestos exposure as the primary cause of malignancy. The longer the asbestos exposure, the more is the risk of a person developing mesothelioma. It can take a minimum of ten and a maximum of 50 years before the symptoms start to appear.
Intratumoral Cancer Therapy: A Potential Weapon To Fight the Battle Against Cancer
Cancer is a leading cause of global death, accounting for nearly 10 million deaths in 2020. However, over the past years, the treatment paradigm of Cancer has transformed with several therapies such as chemotherapies, radiation therapies, and immunotherapies available to treat cancer.
Case Study
A United States-based pharmaceutical working in the cancer immunotherapy domain approached DelveInsight to assist in analyzing the current pipeline activity as well as R&D of T-Cell Receptor (TCR) products for cancer treatment. DelveInsight proceeded with assessment of the pipeline, clinical trial details, Funding/Collaboration/Partnership Analysis, and R&D in the TCR domain.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com
